CIK 0001438533 · Large accelerated filer
Travere Therapeutics, Inc.
Sign in to watch- Ticker
- TVTX
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- CA
- Entity type
- operating
- EIN
- 262383102
- Phone
- 888-969-7879
- Business address
- 3611 VALLEY CENTRE DR, SUITE 300, SAN DIEGO, CA, 92130
- Former names
- Retrophin, Inc., Desert Gateway, Inc.
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $80,128,453
- in 11 filings, $80.1M under 10b5-1 plans
Net −$80,128,453. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
- Dube Eric M −$38.5M CHIEF EXECUTIVE OFFICER sold 60% of stake
- Heerma Peter −$17.9M EVP, CHIEF COMMERCIAL OFFICER sold 71% of stake
- ROTE WILLIAM E. −$13.1M Chief Research Officer sold 68% of stake
- Cline Christopher R. −$3.2M CHIEF FINANCIAL OFFICER sold 37% of stake
- Inrig Jula −$2.8M EVP, Head of R&D & CMO sold 31% of stake
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2026-10-15 | Dube Eric M CHIEF EXECUTIVE OFFICER | Option exercise 10b5-1 | +43,735 | $26.88 | $1.2M | 476,621 |
| 2026-10-15 | Dube Eric M CHIEF EXECUTIVE OFFICER | Option exercise 10b5-1 | +200,000 | $8.93 | $1.8M | 676,621 |
| 2026-10-15 | Dube Eric M CHIEF EXECUTIVE OFFICER | Sale 10b5-1 | −128,065 | $52.97 | $6.8M | 548,556 |
| 2026-10-15 | Dube Eric M CHIEF EXECUTIVE OFFICER | Sale 10b5-1 | −37,270 | $54.20 | $2.0M | 511,286 |
| 2026-10-15 | Dube Eric M CHIEF EXECUTIVE OFFICER | Sale 10b5-1 | −78,400 | $55.02 | $4.3M | 432,886 |
| 2026-10-15 | Dube Eric M CHIEF EXECUTIVE OFFICER | Option exercise · Employee stock option (right to buy) 10b5-1 | −43,735 | 168,925 | ||
| 2026-10-15 | Dube Eric M CHIEF EXECUTIVE OFFICER | Option exercise · Employee stock option (right to buy) 10b5-1 | −200,000 | 160,000 | ||
| 2026-09-17 | Heerma Peter EVP, CHIEF COMMERCIAL OFFICER | Option exercise 10b5-1 | +8,282 | $22.40 | $186K | 125,348 |
| 2026-09-17 | Heerma Peter EVP, CHIEF COMMERCIAL OFFICER | Sale 10b5-1 | −8,282 | $65.07 | $539K | 117,066 |
| 2026-09-17 | Heerma Peter EVP, CHIEF COMMERCIAL OFFICER | Option exercise · Employee stock option (right to buy) 10b5-1 | −8,282 | 44,837 | ||
| 2026-09-17 | Dube Eric M CHIEF EXECUTIVE OFFICER | Option exercise 10b5-1 | +108,493 | $23.34 | $2.5M | 541,379 |
| 2026-09-17 | Dube Eric M CHIEF EXECUTIVE OFFICER | Sale 10b5-1 | −101,691 | $64.59 | $6.6M | 439,688 |
| 2026-09-17 | Dube Eric M CHIEF EXECUTIVE OFFICER | Sale 10b5-1 | −6,802 | $64.95 | $442K | 432,886 |
| 2026-09-17 | Dube Eric M CHIEF EXECUTIVE OFFICER | Option exercise · Employee stock option (right to buy) 10b5-1 | −108,493 | 0 | ||
| 2026-09-16 | Heerma Peter EVP, CHIEF COMMERCIAL OFFICER | Option exercise 10b5-1 | +100,000 | $11.25 | $1.1M | 217,066 |
| 2026-09-16 | Heerma Peter EVP, CHIEF COMMERCIAL OFFICER | Option exercise 10b5-1 | +55,000 | $15.46 | $850K | 272,066 |
| 2026-09-16 | Heerma Peter EVP, CHIEF COMMERCIAL OFFICER | Option exercise 10b5-1 | +17,717 | $26.88 | $476K | 289,783 |
| 2026-09-16 | Heerma Peter EVP, CHIEF COMMERCIAL OFFICER | Sale 10b5-1 | −93,604 | $63.25 | $5.9M | 196,179 |
| 2026-09-16 | Heerma Peter EVP, CHIEF COMMERCIAL OFFICER | Sale 10b5-1 | −79,113 | $63.65 | $5.0M | 117,066 |
| 2026-09-16 | Heerma Peter EVP, CHIEF COMMERCIAL OFFICER | Option exercise · Employee stock option (right to buy) 10b5-1 | −100,000 | 0 |
Page 1 of 41 · 802 trades